mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-Cov-2 variants | Centers for Disease Control and Prevention |
---|---|
Use of Pfizer-BioNTech COVID-19 vaccine: Clinical considerations | Interim considerations for COVID-19 vaccination of healthcare personnel and long-term care facility residents |
Moderna announces primary efficacy analysis in phase 3 COVE study for its COVID-19 vaccine candidate and filing today with the U.
21Centers for Disease Control and Prevention | Centers for Disease Control and Prevention |
---|---|
Vaccination considerations for persons with underlying medication conditions | Officials discuss COVID-19 vaccine deliveries prioritization criteria |
Centers for Disease Control and Prevention.
6